Printer Friendly

Medivir reports on termination of simeprevir license by Janssen.

M2 EQUITYBITES-December 11, 2017-Medivir reports on termination of simeprevir license by Janssen

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Medivir AB (STO: MVIR) announced on Sunday that Janssen Pharmaceuticals Inc (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen's assessment of market demand.

This termination of the license will become effective in June 2018 and Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time.

Also, Medivir will seek to identify potential commercialisation partners for specific territories where it believes there may be a market opportunity.

Reportedly, Medivir's royalty on the global sales of simeprevir in the first three quarters of 2017 were SEK13.7m, SEK7.7m and SEK4.1m.

Medivir is a research-based pharmaceutical company with a focus on oncology.

(EUR1.00=SEK9.95)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 11, 2017
Words:154
Previous Article:Impax wins US FDA tentative approval for generic Coreg CR ER capsules.
Next Article:Macy's announces retirement of executive chairman Terry Lundgren.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters